Articles tagged with Prostate Cancer
A new $4 million grant will test whether Prostate Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) Computed Tomography (CT) can improve prostate cancer monitoring while reducing screening-related harms. The study aims to reduce the need for biopsies in men with low- or intermediate-risk prostate cancers.
A new study by UCLA researchers shows that advanced MRI imaging and targeted focal therapy can help many men with low- to intermediate-risk prostate cancer safely stay on active surveillance long-term, avoiding follow-up biopsies and delaying or avoiding invasive treatments. The findings suggest that routine follow-up biopsy can now be...
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.
A recent study has identified similarities in the mechanisms of diabetes and prostate cancer, suggesting that diabetes drugs like pioglitazone could inhibit tumor growth. Researchers found that PPARγ activation states influence cell behavior, leading to potential new therapeutic approaches for prostate cancer treatment.
A phase III clinical trial has shown that a two-and-a-half week course of precision radiotherapy is equally successful in beating prostate cancer as the standard eight-week approach. After 10 years, both options produced similar disease control rates and survival rates.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Researchers at TUM developed an AI-powered algorithm to predict kidney damage in prostate cancer patients undergoing lutetium-177 PSMA therapy. Early detection could enable personalized treatment adjustments to prevent organ damage.
Researchers at Karolinska Institutet have identified new biomarkers in urine that can indicate the presence and severity of prostate cancer with high precision. The findings surpass current blood biomarker PSA in terms of diagnostic accuracy.
Researchers have discovered genetic properties in prostate cancer that can be targeted to improve patient outcomes, particularly for Chinese men. The findings highlight the potential of precision medicine and more effective treatments.
Hyperbaric oxygen treatment has been shown to provide long-term relief for patients with late radiation-induced injuries, improving symptoms of urinary incontinence, bleeding, and severe pain. The treatment can lead to the healing of chronic injuries and allow patients to live a fully normal life.
A recent preclinical study from Weill Cornell Medicine researchers suggests that three-dimensional gene hubs may promote brain cancer. The findings, published in Molecular Cell, offer a new way to think about cancer beyond gene mutations and highlight the importance of understanding DNA organization in tumor cells.
Researchers from the University of California - Los Angeles Health Sciences will present new research findings on robotic prostate cancer surgery and cost-effectiveness of pembrolizumab in high-risk bladder cancer. The innovations aim to improve patient outcomes and advance the field of urology.
A new study finds that a specific genetic variation in the PTGS2 gene is associated with an increased risk of benign prostate hyperplasia (BPH) in Lebanese men. Men carrying the C version of this gene were more than twice as likely to have BPH compared to those without it.
A UCLA study validates the predictive power of PROSTOX, a genetic test that uses microRNAs to identify patients at higher risk of developing long-lasting urinary side effects from radiation therapy. The test helps doctors and patients choose safer treatment options, reducing the burden of long-term complications.
Researchers discovered TBX2 drives therapy resistance by shifting signaling from the androgen receptor to the glucocorticoid receptor. The study identified a strategy to target this switch, potentially predicting patient risk and offering new treatment approaches.
A new study found significant disparities in the use of MRI to detect prostate cancer, with Black patients and those in rural areas having lower rates of diagnostic testing. The study's findings highlight the need for enhanced access to MRI and improved prostate cancer outcomes.
The national healthcare initiative has been extended for five years to provide world-class healthcare services to every Guyanese citizen. The partnership will establish a national cancer center, modernize national health facilities, and implement an advanced digital health system.
Researchers mapped m6A patterns across 162 prostate cancer tumors and found that these modifications were closely tied to tumor aggressiveness. Analyzing m6A tags could help doctors predict disease behavior and determine personalized treatment strategies for patients with prostate cancer.
A new surgical technique called NeuroSAFE has been shown to preserve erectile function in men with prostate cancer, with 39% of patients experiencing no or mild dysfunction after treatment. This is compared to 23% of those who received standard surgery.
A new study has shown that high-resolution ultrasound can diagnose prostate cancer as effectively as MRI, with improved resolution and lower costs. The technology, called micro-ultrasound, is expected to speed up diagnosis, reduce hospital visits, and make imaging more accessible, particularly in less developed healthcare systems.
A new editorial highlights a growing concern in cancer care: radiotherapy may leave behind residual disease that can lead to worse long-term outcomes. Studies have shown that patients with residual disease are more likely to experience cancer recurrence and shorter survival, emphasizing the need for regular biopsy-based tests.
A sub-analysis of 20-year follow-up data from the European Randomized study of Screening for Prostate Cancer (ERSPC) reveals that men who consistently decline prostate cancer screening appointments have a 45% higher risk of dying from the disease compared to those who attend screening appointments.
A Rice University statistician has received a $1 million CPRIT award to advance AI-powered precision medicine for prostate cancer. The project aims to identify lethal forms of prostate cancer earlier and improve treatment selection using AI tools and advanced imaging techniques.
A new study confirms that a shorter, higher-dose-per-day radiation course is as effective as conventional radiotherapy for treating early-stage prostate cancer without increasing side effects. The study found similar cancer control rates and fewer gastrointestinal issues with the new approach.
Researchers developed an AI tool called Unfold AI to accurately estimate prostate tumor volume and identify patients likely to benefit from partial gland cryoablation. This approach shows promise in reducing treatment failures by over 70% and improving patient outcomes.
Researchers found that the current standard monitoring time of one-and-a-half to two months following surgery is too short to accurately identify recurrence and inform treatment decisions. Monitoring PSA levels for at least three months can avoid overtreatment and mislabel patients as having recurred.
A new study from Edith Cowan University found that regular exercise significantly improved erectile function in patients with prostate cancer. The research suggests that exercise medicine should be considered a key part of their treatment, and may help address relationship issues caused by sexual dysfunction.
Active surveillance is an extremely safe option for prostate cancer patients, with a 0.1% mortality rate after 10 years. A personalized approach to treatment is necessary, taking into account the patient's age and disease stage.
Researchers found that aspirin prevents cancers from spreading by decreasing a clotting factor called thromboxane A2 and releasing T cells from suppression. This discovery could lead to the development of targeted treatments to prevent cancer metastasis, making aspirin potentially less expensive than antibody-based therapies.
Researchers at University of Arizona Cancer Center found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined with a specific protein inhibitor. The study's co-author, Noel Warfel, PhD, identified a way to sensitize prostate tumors to immune checkpoint inhibitors ...
A study uncovered new genetic clues explaining why some prostate cancers grow slowly while others become life-threatening, identifying 223 mutations that determine tumor progression. The research shows germline and somatic variability work together to initiate and drive prostate cancer.
Researchers have developed a new strategy to protect cancer patients from radiation-induced DNA damage using a protein from tardigrades. The approach makes use of messenger RNA encoding the protein, which is delivered to patient tissues before radiation treatment. This reduces double-stranded DNA breaks by 50% in mouse models.
A large-scale study has found huge variation in GP practices on prostate cancer testing, with one in five patients diagnosed without symptoms. The study suggests a need for more consistent approach to testing people without symptoms to redress the imbalance.
A new study by Rice University and Vanderbilt University researchers found that combining focused ultrasound with the existing protein therapy TRAIL can significantly reduce tumor size and burden in prostate cancer models. The therapy works by amplifying the anticancer effects of TRAIL via Piezo1 activation, which triggers cell death.
A study found that pro-inflammatory molecules contribute to benign prostatic hyperplasia (BPH) in aging men, especially those with metabolic syndrome. Men with BPH had higher levels of pro-inflammatory markers and lower anti-inflammatory substances, suggesting a link between inflammation and prostate conditions.
A recent study reveals genes that may help predict prostate cancer outcomes, including androgen receptor AR-V7 and p160 gene family. The research suggests these genes could serve as potential prognostic biomarkers for prostate cancer, highlighting the importance of androgen signaling in disease progression.
A new laparoscopic imaging technique uses stereo depth estimation and speckle-illumination SFDI to accurately map the optical properties of biological tissue. The device provides detailed optical property maps, enabling surgeons to identify critical tumor margins and improve clinical outcomes.
Donald Patrick McDonnell, a professor at Duke University School of Medicine, has been awarded the Endocrine Society's John D. Baxter Prize for his research on hormone therapies for treating breast and prostate cancers. His work led to the discovery of novel treatments for these cancers and has improved patient care.
A new study found that RAD51 testing can complement next-generation sequencing in personalizing prostate cancer treatment, especially for patients with homologous recombination repair-defective tumors. The biomarker showed high sensitivity and specificity for identifying BRCA1/2 alterations.
Researchers at UCSF used CRISPR gene editing technology to transform ordinary white fat cells into 'beige' fat cells that voraciously consume calories to make heat. Implanted near tumors, these cells outcompeted cancer cells for nutrients, beating back five types of cancer in lab experiments.
A new study by UC San Francisco found a marked increase in advanced prostate cancer rates across California since doctors stopped routine screening, with death rates plateauing in most regions. The study emphasizes the need for screening that can identify fatal tumors without raising false alarms.
A new urine test for prostate cancer has been shown to be highly accurate and can be used at home. The test, known as MyProstateScore 2.0 (MPS2), analyzes 18 genes associated with prostate cancer and can rule out clinically significant cancers with high accuracy.
A recent study published in Lancet Oncology reveals a significant link between early side effects from radiation therapy for prostate cancer and long-term complications. Men who experience moderate acute urinary or bowel side effects during treatment are nearly twice as likely to develop late urinary or bowel issues, respectively. This...
The latest therapeutic strategies for castration-resistant prostate cancer focus on innovative proteolysis-targeting chimera (PROTAC) technology, which degrades target proteins and holds potential as effective treatments. PROTAC technology is a novel means to combat resistance mechanisms in PRPC.
A study of men with a family history of prostate cancer discovered an inherited form of prostate cancer linked to the mutated gene WNT9B. This gene variant increases prostate cancer risk by two- to 12-fold, comparable to breast cancer risk conferred by pathogenic mutations.
Researchers have clinically validated a urine test that can detect aggressive prostate cancer, potentially avoiding unnecessary biopsies and overtreatment. The test, called MyProstateScore 2.0, analyzes 18 genes linked to high-grade prostate cancer and showed a 94% sensitivity rate.
A systematic review found that genomic classifier tests can influence risk classifications and treatment decisions for patients with localized prostate cancer, but more research is needed to understand their cost-effectiveness and impact on racial groups. The tests may lead to more conservative management options, such as active survei...
A group of Chinese experts has developed a comprehensive consensus aimed at addressing critical gaps in prostate cancer management. The consensus recommends starting PSA screening at age 50 and endorsing the use of next-generation hormonal agents combined with ADT for high-volume metastatic castration-sensitive prostate cancer patients.
The new NCCN Guidelines for Patients: Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancer provide evidence-based recommendations for assessing and testing for inherited genetic mutations. The resource aims to inform individuals about their cancer risks based on personal or family history.
Researchers developed a novel approach using lipid nanoparticles to deliver mRNA and siRNA, restoring tumor suppressors and inhibiting tumor drivers in prostate cancer cells. This technique holds promise for treating various types of cancer by targeting specific pathways related to tumor growth and suppression.
Researchers are investigating a water vapor system that uses small, targeted amounts of steam to kill cancer cells in patients with intermediate-risk prostate cancer. The trial aims to explore the safety and effectiveness of this treatment as an alternative to traditional therapies, which can cause life-altering side effects.
A new study found that nearly half of high-risk prostate cancer patients have metastatic disease when evaluated with advanced PSMA-PET imaging, suggesting traditional imaging may underestimate cancer spread. This challenge the interpretation of previous studies like EMBARK trial, and support the inclusion of PSMA-PET for patient select...
Most study participants struggled to understand standard prostate cancer pathology reports, but found patient-centered reports easier to comprehend. PCPRs reduced perceived worry in low-risk conditions compared to traditional reports, suggesting their inclusion could enhance patient care.
A study by Charité – Universitätsmedizin Berlin found that an MRI-first approach to detecting prostate cancer is safe and reliable, with normal MRI findings indicating a low risk of aggressive cancer. The strategy involves regular urological checks instead of biopsies for patients without suspicious findings.
Researchers discovered a novel vulnerability in prostate cancer cells that starves them of critical nutrients called amino acids. By inhibiting two proteins, GCN2 and p53, the team found a way to effectively destroy prostate tumors.
Researchers discovered a novel platinum complex that targets androgen receptor signaling, inhibiting cell growth and survival in prostate cancer cells. The complex, 5-H-Y, showed stronger cytotoxic effects than cisplatin with minimal toxicity, offering a promising approach to treating advanced prostate cancer.
A new study found that a low omega-6, high omega-3 diet with fish oil supplements significantly reduced prostate cancer cell proliferation in men. The findings suggest that dietary changes could potentially delay or prevent the need for more aggressive treatments.
Researchers at MSU are developing a novel approach to combat prostate cancer using promethium-149, a radioactive isotope that can deliver high doses of radiation directly to cancer cells. The team plans to test the effectiveness of 149Pm against industry-standard 177Lu and explore its potential for treating other types of cancers.
A new DNA sequencing test called AR-ctDETECT has been found to distinguish between patients with poor and favorable prognoses in advanced prostate cancer. The test identified circulating tumor DNA in 59% of patients and showed that detectable ctDNA was associated with worse overall survival.
The study estimated that prevention, screening, and treatment efforts in the US led to an average of 8 out of 10 cancer deaths being avoided for breast, cervical, colorectal, lung, and prostate cancers combined. The total number of averted cancer deaths was approximately 5.94 million between 1975 and 2020.